HOME ·

R&D Progress

HENGRUI PHARMA (01276.HK): Marketing Application for Class 1 Innovative Drug SHR-2004 Injection Accepted by NMPA for VTE Prevention After Knee Replacement Surgery
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-14
CMS (00867.HK): Innovative Drug CMS-D001, a Highly Selective TYK2 Inhibitor, Receives Drug Clinical Trial Approval Notice for Systemic Lupus Erythematosus Indication
Tags：
CMS00867.HKR&D Progress
2026-09-14
CSPC PHARMA (01093.HK): Phase I/II Data of SYS6010 Combined with Enlangsuba Monoclonal Antibody in Previously Untreated Driver-Gene-Negative Advanced NSCLC Presented as Oral Presentation at 2026 WCLC
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-14
LEADS BIOLABS-B (09887.HK): Updated Phase II Data of Vilxin® Combined with Chemotherapy as First-Line Treatment for NSCLC Presented in Oral Presentation at WCLC 2026
Tags：
LEADS BIOLABS-B09887.HKR&D Progress
2026-09-14
PEIJIA-B (09996.HK): NMPA Approval for Registration Application of GeminiOne® Transcatheter Edge-to-Edge Repair System
Tags：
PEIJIA-B09996.HKR&D Progress
2026-09-11
HENGRUI PHARMA (01276.HK): HER3 ADC Ruzaltatug Rezetecan granted breakthrough therapy designation
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-11
FOSUN PHARMA (02196.HK): Registration application for new specification of HLX14 denosumab biosimilar accepted by NMPA
Tags：
FOSUN PHARMA02196.HKR&D Progress
2026-09-11
HANSOH PHARMA (03692.HK): Small Cell Lung Cancer Product HS-20093 Included in NMPA Priority Review Procedure
Tags：
HANSOH PHARMA03692.HKR&D Progress
2026-09-11
OCUMENSION-B (01477.HK): NDA for OT-301 in Open-Angle Glaucoma or Ocular Hypertension Accepted by NMPA
Tags：
OCUMENSION-B01477.HKR&D Progress
2026-09-11
HENGRUI PHARMA (01276.HK): Hetrombopag Olamine Tablets approved for two additional indications, becoming world's first TPO-RA approved for CTIT
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-10
SSY GROUP (02005.HK): Wins NMPA approval for Letermovir Injection, deemed to have passed consistency evaluation
Tags：
SSY Group02005.HKR&D Progress
2026-09-10
INSILICO (03696.HK): AI-Driven Candidate Rentosertib Completes First Patient Dosing in Phase III IPF Trial
Tags：
Insilico03696.HKR&D Progress
2026-09-10
LIFETECH SCI (01302.HK): Aortic Valve Replacement System Enters NMPA Innovative Medical Device Special Review Procedure
Tags：
LIFETECH SCI01302.HKR&D Progress
2026-09-10
STAR SPORTS MED (01609.HK): First Chinese Sports Medicine Manufacturer with Full Product Line EU CE MDR Certified
Tags：
STAR SPORTS MED01609.HKR&D Progress
2026-09-10
HBM HOLDINGS-B (02142.HK): Partner Solstice Oncology Closes USD 225 Million Series A Financing
Tags：
HBM HOLDINGS-B02142.HKR&D Progressfinancing
2026-09-09
HENGRUI PHARMA (01276.HK): NMPA Accepts Marketing Application for Ruippotipeptide Injection for Adults with Type 2 Diabetes
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-09
CSPC PHARMA (01093.HK): SYH9087, China's First Subcutaneous Rotigotine Long-acting Product, Cleared for Clinical Trials
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-09
HBM HOLDINGS-B (02142.HK): Positive Phase II Interim Results for HBM9378/WIN378 in Asthma; Phase III Initiated
Tags：
HBM HOLDINGS-B02142.HKR&D Progress
2026-09-08
SKB BIO (06990.HK): Positive Phase II Interim Results for SKB378/WIN378 in Asthma; Phase III Initiated
Tags：
SKB BIO06990.HKR&D Progress
2026-09-08
ASCLETIS-B (01672.HK): Initiates US Phase I Study of Oral Amylin Receptor Agonist Peptide ASC36 for Obesity; Up to 13.2% Weight Loss in Non-human Primates
Tags：
ASCLETIS-B01672.HKR&D Progress
2026-09-08
Previous12 345..6